Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | CLEC4M | Q9H2X3 | 2/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25505637 | 1.00 | LGALS3 (0.44) | LGALS3OPRM1PKMXIAPBIRC2 | |
| SCHEMBL25979427 | 0.95 | LGALS3 (0.44) | LGALS3CLEC4M | |
| SCHEMBL25523254 | 0.94 | LGALS3 (0.42) | LGALS3CLEC4M | |
| SCHEMBL25523320 | 0.93 | LGALS3 (0.41) | LGALS3CLEC4M | |
| SCHEMBL25983012 | 0.92 | LGALS3 (0.40) | LGALS3CLEC4M | |
| SCHEMBL25979532 | 0.90 | LGALS3 (0.40) | LGALS3CLEC4M | |
| SCHEMBL25979459 | 0.90 | LGALS3 (0.39) | LGALS3CLEC4M | |
| SCHEMBL29332026 | 0.89 | LGALS3 (0.37) | LGALS3OPRM1XIAPBIRC2F2RL1 | |
| SCHEMBL25495188 | 0.87 | LGALS3 (0.50) | LGALS3OPRM1PKMXIAPBIRC2 | |
| SCHEMBL25979709 | 0.87 | LGALS3 (0.39) | LGALS3OPRM1PKMCLEC4M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | LGALS3 293/4885OPRM1 1331/4885PKM 2229/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | LGALS3 264/4885OPRM1 3060/4885PKM 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.